The Center
Multiple Sclerosis Center Dresden
Patient Information
Contact MSC
Physicians & Nurses
Study Team
Neuropsychology
Mobility Center
The Mobility Center
Walking Assessment
Jump Assessment
DIERS
EMIQ
Projects
Neuroimmunological Laboratory
The NIL
Neurofilament light chain
Autonomic & Neuroendocrinological Functional Laboratory
The ANF
ANF Assessment
MS Living Lab
Management & Science
Team Management & Science
Projects
eHealth & Analytics
MSDS 3D
MSDS Clinic & Practice
MS-HRS
MTRS
Multiple Sclerosis Management
Aktuelles
Neuigkeiten
Publikationen
Veranstaltungen
Adventssymposium
Multiple Sklerose 360°
Welt-MS-Tag 2021
Doktorarbeiten
Jobs
Kontakt
Podcasts & Newsletter
Newsletter
Patienten-Podcast
Ärzte-Podcast
Neurovision
Immune cell calender 25
Sherlock-MS-Blog
Studien
Interventionelle Studien
B-SHUTTLE
Nicht-interventionelle Studien
MS PATHS
Konectom
Sprachanalyse
English (UK)
Deutsch
English (UK)
Long-Term Immune Response Profiles to SARS-CoV-2 Vaccination and Infection in People with Multiple Sclerosis on Anti-CD20 Therapy
NIL
Jahr
Publikationsjahr
2023
Autoren
Autorenliste der Publikation
Woopen C, Dunsche M, Al Rahbani GK, Dillenseger A, Atta Y, Haase R, Raposo C, Pedotti R, Ziemssen T, Akgün K.
Verlag
Publisher-Information
Vaccines (Basel). 2023 Sep 7;11(9):1464.
Link
Zur Publikation (externer Server)
https://doi.org/10.3390/vaccines11091464
Tags
Forschungsthemen
Multiple Sklerose
Neuroimmunologie
MSZ
NIL
2023
Long-Term Treatment With Ocrelizumab in Patients With Early-Stage Relapsing MS
MS Treatments
Jahr
2025
Digital Representation of Patients as Medical Digital Twins: Data-Centric Viewpoint
MASC
Jahr
2025
A plain language summary of a study exploring the experiences of people with relapsing–remitting multiple sclerosis: what symptoms and impacts of the disease matter most and how can they be evaluated better?
MS Treatments
Jahr
2025
Cost–consequence analysis of early vs. delayed natalizumab use in highly active relapsing–remitting multiple sclerosis: a simulation study
MASC
Jahr
2025
Funktionelle Elektrostimulation zur Versorgung bei paretischen Gangstörungen: Fokus auf Fußheberschwäche bei Multipler Sklerose
Mobility
Jahr
2024